Meeting
2017 ASCO Annual Meeting
A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
Authors
Mark T. Fleming
Virginia Oncology Associates, Norfolk, VA
Mark T. Fleming , Richard Cathomas , Daniel Peter Petrylak , Judy Sing-Zan Wang , Neil Harrison Bander , Francesca Zammarchi , Patrick H. van Berkel , Song Hye Cho , Nairouz Elgeioushi , John Bothos , Anita Scheuber , Johann de Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02991911
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5088)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5088
Abstract #
TPS5088
Poster Bd #
161a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: W. Kevin Kelly
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew Leonard Laccetti
Poster
2022 ASCO Annual Meeting
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Costin Danila
Poster
2021 Genitourinary Cancers Symposium
Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: William Kevin Kelly